Should I Buy KTTA Stock in 2026?
Data-driven analysis and honest assessment for Pasithea Therapeutics Corp
Current Price: $0.74
Decision Score
Weak
Based on 6 fundamental factors
Score Breakdown:
P/E data not available
Moderate growth of 7%
Currently unprofitable
Financial health data limited
Negative free cash flow
No recent insider activity
Key Investment Metrics
Current Price
$0.74
P/E Ratio
N/A
Revenue Growth
15.0%
Profit Margin
N/A
Market Cap
$0.0B
Dividend Yield
None
How KTTA Compares to Competitors
Understanding how KTTA stacks up against peers helps inform your investment decision.
How KTTA Compares to Peers
Upcoming Events for KTTA
+5 Reasons TO Buy KTTA
1. Steady revenue growth of 15%
weakConsistent revenue growth demonstrates business stability and market share maintenance.
-5 Reasons NOT to Buy KTTA
1. Negative free cash flow
high riskBurning cash creates funding risk and limits shareholder returns.
2. Small-cap volatility risk
high riskMarket cap under $2B means higher volatility and lower liquidity.
Who Should Buy KTTA?
Investment Profile
Risk Level
Very High
Recommended Holding Period
3-5 years
Best For:
Not Suitable For:
- ✗
Growth Investors
Limited 15% growth may disappoint
- ✗
Income-Focused Retirees
No dividend paid
- ✗
Risk-Averse Investors
Very High risk may cause uncomfortable volatility
- ✗
Large Position Traders
Lower liquidity may impact execution
Consider These Alternatives
If you're interested in KTTA, compare these Health Care peers:
Pro tip: Compare KTTA directly with competitors using our comparison tool to see which stock better fits your criteria.
Get the Full Picture
Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for KTTA
Frequently Asked Questions
What is KTTA stock price today?
KTTA (Pasithea Therapeutics Corp) stock is trading at $0.74 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).
Is KTTA stock going up or down today?
KTTA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.
Should I buy KTTA stock now?
The decision to buy KTTA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.
Is KTTA a buy, hold, or sell right now?
Our AI-powered analysis provides buy/hold/sell recommendations for KTTA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.
Is KTTA stock overvalued or undervalued?
Use our DCF valuation calculator to determine if KTTA is overvalued or undervalued based on fundamental analysis and future cash flow projections.
What is KTTA's P/E ratio?
P/E ratio data for KTTA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.
What is KTTA's market cap?
KTTA (Pasithea Therapeutics Corp) has a market capitalization of $0.02 billion, making it a small-cap stock.
What is KTTA's price to book ratio?
KTTA trades at a price-to-book (P/B) ratio of 0.34, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.
Deep Dive Analysis
Explore comprehensive analysis tools to make an informed decision about Pasithea Therapeutics Corp
Full Stock Analysis
Complete KTTA overview with charts and data
Is KTTA Undervalued?
DCF valuation and intrinsic value analysis
Dividend Analysis
Yield, payout ratio, and dividend history
Growth Analysis
Revenue, earnings, and expansion metrics
Financial Health
Debt, liquidity, and balance sheet strength
Price Prediction
2026 forecast and price targets
Stock Forecast
12-month price forecast and analyst targets
Earnings Date
Next earnings date and historical results
Compare Before You Buy
See how KTTA stacks up against its competitors
Similar Investment Decisions
Explore investment analyses for stocks similar to Pasithea Therapeutics Corp
Complete KTTA Analysis
Compare KTTA With
Disclaimer
This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.